Showing 1,095 results

Filters Content type: News, Editors' picks Topic: Hepatitis C treatment

Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

Hepatitis C treatment

Fighting for their lives: Economist Intelligence Unit report finds patient groups lead global efforts to address hepatitis C

Editor's pick
Janssen press release
25 June 2014
Hepatitis C treatment

2014 UK Consensus Guidelines — Hepatitis C Management and Direct-acting Anti-viral Therapy

Editor's pick
Medscape (requires registration)
19 June 2014
New & experimental hepatitis C treatment

UNITED STATES: FDA Approves AbbVie's Hepatitis C Regimen for Priority Review

Editor's pick
CDC
19 June 2014
Hepatitis C treatment

NICE rejection looms for Sovaldi

Editor's pick
Pharmafile
16 June 2014
Hepatitis C treatment

Low uptake of HCV treatment in England will lead to substantial disease burden by 2035

News
13 June 2014
Pharmaceutical industry

FDA lifts hold on Achillion's hepatitis C drug, shares jump

Editor's pick
Reuters
11 June 2014
Hepatitis C treatment

Why The Hepatitis C Cost Cutters May Have Already Lost

Editor's pick
Forbes
11 June 2014
Hepatitis C treatment

Why is the $1,000 pill cheaper in the UK?

Editor's pick
Columbia Journalism Review
10 June 2014
Hepatitis C treatment

England: New study reveals the costs of low uptake of hepatitis C treatment

Editor's pick
Public Health England (press release)
10 June 2014
New & experimental hepatitis C treatment

Why Merck Just Spent $4 Billion On New Drugs For Hepatitis C

Editor's pick
Forbes
9 June 2014
Access to healthcare

WHA Adopts Resolution On Hepatitis; Member States Concerned Over High Prices

Editor's pick
Intellectual Property Watch
23 May 2014
Hepatitis C treatment

Today new hepatitis resolution is passed at world health assembly; challenges World Health Organization and member states to act

Editor's pick
Treatment Action Group
23 May 2014
Hepatitis C treatment

Defuse Hepatitis C, the Viral Time Bomb: Test and Treat Hepatitis C

Editor's pick
Treatment Action Group
21 May 2014
Hepatitis C treatment

US health insurers say Gilead hepatitis C drug too costly

Editor's pick
Reuters
21 May 2014
Prisoners

To curb hepatitis C, test and treat inmates

Editor's pick
Eurekalert Inf Dis
15 May 2014
New & experimental hepatitis C treatment

AbbVie Submits for EU Marketing Authorization its Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Chronic Hepatitis C

Editor's pick
AbbVie press release
8 May 2014
Hepatitis C treatment

Sofosbuvir + ribavirin is safe and effective for HCV recurrence after liver transplantation

News
8 May 2014
Hepatitis C treatment

ITPCru report: Access to drugs for treating hepatitis C in Russia in 2013

Editor's pick
EATG
8 May 2014
Hepatitis C treatment

Janssen submits US FDA new drug application for simeprevir / sofosbuvir combination use

Editor's pick
Janssen press release
8 May 2014
Access to healthcare

UNITAID approves grants of $160 million, for hepatitis C, MDR-TB and malaria drugs

Editor's pick
UNITAID
7 May 2014
Hepatitis C transmission & prevention

UK - 'Eradicating hepatitis C is a realistic aim'

Editor's pick
Health Service Journal
6 May 2014
Hepatitis C treatment

Sustained response to treatment reduces fatigue in hepatitis C patients

News
6 May 2014
Pharmaceutical industry

Vertex ends hepatitis C investment as sales fall

Editor's pick
CNBC
2 May 2014
Hepatitis C treatment

Sofosbuvir + ribavirin for 24 weeks is highly effective against HCV genotype 4

News
2 May 2014